Corrigendum: Identification of novel therapeutic candidates against SARS-CoV-2 infections: An application of RNA sequencing toward mRNA based nanotherapeutics

Front Microbiol. 2022 Oct 21:13:1059437. doi: 10.3389/fmicb.2022.1059437. eCollection 2022.

Zunera Khalid¹, Ma Huan¹, Muhammad Sohail Raza^{2

3

4}, Misbah Abbas⁵, Zara Naz⁵, Arnaud John Kombe Kombe⁵, Weihong Zeng⁵, Hongliang He⁶, Tengchuan Jin^{1

5

7}

¹ Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
² CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
³ China National Center for Bioinformation, Beijing, China.
⁴ University of Chinese Academy of Sciences, Beijing, China.
⁵ CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
⁶ Department of Infectious Diseases, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
⁷ CAS Center for Excellence in Molecular Cell Science, Shanghai, China.

Abstract

[This corrects the article DOI: 10.3389/fmicb.2022.901848.].

Keywords: COVID-19 management; PBMCs; RNA sequencing; SARS-CoV-2; mRNA based nanotherapeutics; upregulated genes.